Navigation Links
FDA has Granted HUD (Humanitarian Use Device) Designation to ITGI's Pericardium Covered Stents, Over and Under(R) and Aneugraft(R), for Treatment of Perforations and Dissections of Native Coronary Arteries and Saphenous Vein Grafts
Date:4/28/2009

OR AKIVA, Israel, April 28 /PRNewswire-FirstCall/ -- ITGI Medical, Ltd. (TASE: ITGI) a company engaged in research, development, manufacturing and marketing of heterologous tissue covered stents, announced that the US Food and Drug Administration (FDA) has granted HUD (Humanitarian Use Device) designation to Over and Under(R) and Aneugraft(R) Pericardium Covered Stents for treatment of perforations and dissections of native coronary arteries and Saphenous Vein Grafts.

This is the first step towards obtaining marketing approval.

Over and Under(R) and AneuGraft(R) are stents 100% covered with a heterologous tissue, designed to set a barrier between the coronary blood vessel wall and its lumen. Stents are commercially available in Europe, Israel and Latin America for treatment of Saphenous Vein Graft stenosis, aneurysms and for emergency situations such as perforations.

About Pericardium Covered Stents

Pericardium Covered Stents are unique stents covered with heterologous tissue designed to set a barrier between the blood vessel wall and its lumen. Pericardium Covered Stents are indicated for treatment of bypass stenosis, aneurysms and for emergency situations such as perforations.

About ITGI Medical

ITGI medical is engaged in research and development, manufacturing and marketing of heterologous tissue covered stents. ITGI's stents are already commercially available in Europe, Israel and Latin America. The world stent market has a value estimation of 6.4 Billion USD, of which 37% are generated in the USA.

    Danna Moran
    VP Marketing
    ITGI Medical Ltd.
    P: +972-72-2200335
    dannam@itgimedical.com



'/>"/>
SOURCE ITGI Medical LTD
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
2. Tolera Therapeutics Granted Orphan Drug Designation for Organ Transplant Rejection Drug
3. VIASPACE Granted US Patent
4. Crisis Exemption Granted to Market Avipel(R) Corn Seed Treatment in Louisiana
5. Valdoxan(R) Granted Marketing Authorisation for the Treatment of Major Depressive Episodes in Europe
6. Odyssey Thera Granted U.S. Patent for Novel GPCR Assay Strategy
7. GeneNews granted U.S. patent for Chagas disease based on Sentinel Principle(TM) platform
8. BioLife Solutions Granted European Biopreservation Patent
9. ScinoPharm Granted US Patent for Novel Crystal Forms
10. Memory Pharmaceuticals Granted Extension to Comply with NASDAQ Listing Requirements
11. MonoSol Rx Granted Strategic US Patent for Thin Film Manufacturing Process
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 ... Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 Published ... the peer-reviewed journal from touchONCOLOGY, Andrew D ... cost of cancer care is placing an increasing ... of expensive biologic therapies. With the patents on ...
(Date:6/23/2016)... 22, 2016  Amgen (NASDAQ: AMGN ) ... QB3@953 life sciences incubator to accelerate the development ... laboratory space at QB3@953 was created to help high-potential ... for many early stage organizations - access to laboratory ... Amgen launched two "Amgen Golden Ticket" awards, providing each ...
(Date:6/22/2016)... , June 22, 2016   StockNewsNow.com , The ... Interview with Dr. Nader Pourhassan , President & ... focused on the clinical development and potential commercialization of ... HIV infection, according to the company,s website (see here: ... Tuesday, June 7 th , 2016, at the LD ...
(Date:6/22/2016)... DIEGO , June 22, 2016  Mesa ... has developed a testing platform designed specifically for ... formation of their scientific advisory board (SAB). Approved ... directors, the SAB is chartered to advise on ... disease assay platform. Led by Dr. Steve ...
Breaking Biology Technology:
(Date:5/3/2016)... Lithuania , May 3, 2016  Neurotechnology, ... released the MegaMatcher Automated Biometric Identification System ... of large-scale multi-biometric projects. MegaMatcher ABIS can process ... accuracy using any combination of fingerprint, face or ... MegaMatcher SDK and MegaMatcher Accelerator ...
(Date:4/26/2016)... , April 27, 2016 ... "Global Multi-modal Biometrics Market 2016-2020"  report to their ... , The analysts forecast the global ... of 15.49% during the period 2016-2020.  ... of sectors such as the healthcare, BFSI, transportation, ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
Breaking Biology News(10 mins):